← Eichor
Condition: Refractory Dipg Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Refractory Dipg

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Phase 1/Phase 2 · 1 location(s) · University of Miami · NCT05956821ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Phase 2 · 20 location(s) · Nationwide Children's Hospital · NCT06838676Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Phase 1/Phase 2 · 12 location(s) · Milton S. Hershey Medical Center · NCT06465199Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Gliom
Phase 1 · 1 location(s) · Seattle Children's Hospital · NCT04185038Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.